EAU Session on ‘Management options for metastatic prostate cancer a’UroToday.com – A poster session on ‘Management options for metastatic prostate cancer 1’found in the EAU on Wednesday 21 March 2007. Two posters from this session will be covered here.

Part time Lacked coverage at some point during 2006-2007, alcoholics USA StudyAbout 89.6 million U.S. Citizens under age 65, or about 34.7 percent of the population lack health insurance at some point during 2006-2007, according to a study on Thursday by families USA, the Florida Times – Union published reports . The study, which analyzed Census Bureau data from 2006-2007 and 1999-2000, almost two-thirds of the population, not the lack of health insurance coverage for over six months or more, and that more than half lacked coverage for nine months or longer. In addition , the study found that 79.3 percent of residents who lacked health insurance were from working class families, 6 percent work full time and 8.7 percent employed part-time (CQ HealthBeat, the study also found that non-Hispanic whites accounted for 26 percent of residents who lacked health insurance accounted for, compared with 44.5 percent of non-Hispanic blacks and 60.7 percent of Hispanics (Florida Times – Union, Morning Report USA Executive Director Ron Pollack said: ‘The great number of people without health insurance in the last two years helps to explain why has healthcare, the top domestic issue in the 2008 presidential campaign,’adding: ‘The expansion of health insurance in America is no longer just a question of charity, about other people, but a matter of intense self-interest ‘(CQ HealthBeat, also told Pollack that he did not expect federal measures to address the problem ‘as long as the president in the White House ‘Griggs Griggs, Baton Rouge Advocate.... Arena Pharmaceuticals announced today in that it launched dosing in a Phase 1 clinical trial evaluating APD791, Arena Oral Sex administered to house detected product candidates for the treatment of arterial thromboembolic diseases determined. These Phase 1 study it is planned to registered post for up to 72 healthy adult volunteers and will evaluate mainly the safety and tolerability individual the ascending doses APD791. In addition, the study will also evaluate the pharmacokinetics and pharmacodynamics of APD791. – Advancing APD791 in the Stage 1 expands of our emerging clinical pipeline of novel therapeutic agents and confirmed our R & D capabilities, said Jack Lief, President and CEO Officer.

Arena Pharmaceuticals and Arena are registered service marks of the company have registered. ‘APD ‘is shorthand for Arena Pharmaceuticals Development.